tetano
Editor, Senior Moderator
Cancers (Basel)
. 2022 Apr 13;14(8):1962.
doi: 10.3390/cancers14081962.
Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination
Lorenz Schubert[SUP] 1 [/SUP], Maximilian Koblischke[SUP] 2 [/SUP], Lisa Schneider[SUP] 1 [/SUP], Edit Porpaczy[SUP] 3 [/SUP], Florian Winkler[SUP] 1 4 [/SUP], Ulrich Jaeger[SUP] 3 [/SUP], Stephan Blüml[SUP] 4 [/SUP], Helmuth Haslacher[SUP] 5 [/SUP], Heinz Burgmann[SUP] 1 [/SUP], Judith H Aberle[SUP] 2 [/SUP], Stefan Winkler[SUP] 1 [/SUP], Selma Tobudic[SUP] 1 [/SUP]
Affiliations
Abstract
Here we analyzed SARS-CoV-2-specific antibodies and T-cell responses after two coronavirus disease 2019 vaccinations over a six-month period in patients with hematological malignancies and assessed the effect of a third vaccination in a subgroup. Sixty-six patients and 66 healthy controls were included. After two vaccinations seroconversion was seen in 52% and a T-cell-specific response in 59% of patients compared with 100% in controls (p = 0.001). Risk factors for a poor serological response were age (<65a), history of anti-CD20 therapy within the year preceding vaccination, CD19[SUP]+[/SUP] B-cells < 110/µL, and CD4[SUP]+[/SUP] T-cells > 310/µL. The magnitude of T-cell response was higher in patients <65a and with CD19[SUP]+[/SUP] B-cells < 110/µL. Patients and healthy controls demonstrated a significant decrease in SARS-CoV-2 S antibody levels over the period of six months (p < 0.001). A third vaccination demonstrated a strong serological response in patients who had responded to the previous doses (p < 0.001). The third vaccination yielded seroconversion in three out of 19 patients in those without serological response. We conclude that both humoral and cellular responses after SARS-CoV-2 immunization are impaired in patients with hematological malignancies. A third vaccination enhanced B-cell response in patients who previously responded to the second vaccination but may be of limited benefit in patients without prior seroconversion.
Keywords: COVID-19; clinical trials; hematology–general; vaccine.
. 2022 Apr 13;14(8):1962.
doi: 10.3390/cancers14081962.
Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination
Lorenz Schubert[SUP] 1 [/SUP], Maximilian Koblischke[SUP] 2 [/SUP], Lisa Schneider[SUP] 1 [/SUP], Edit Porpaczy[SUP] 3 [/SUP], Florian Winkler[SUP] 1 4 [/SUP], Ulrich Jaeger[SUP] 3 [/SUP], Stephan Blüml[SUP] 4 [/SUP], Helmuth Haslacher[SUP] 5 [/SUP], Heinz Burgmann[SUP] 1 [/SUP], Judith H Aberle[SUP] 2 [/SUP], Stefan Winkler[SUP] 1 [/SUP], Selma Tobudic[SUP] 1 [/SUP]
Affiliations
- PMID: 35454867
- PMCID: PMC9032993
- DOI: 10.3390/cancers14081962
Abstract
Here we analyzed SARS-CoV-2-specific antibodies and T-cell responses after two coronavirus disease 2019 vaccinations over a six-month period in patients with hematological malignancies and assessed the effect of a third vaccination in a subgroup. Sixty-six patients and 66 healthy controls were included. After two vaccinations seroconversion was seen in 52% and a T-cell-specific response in 59% of patients compared with 100% in controls (p = 0.001). Risk factors for a poor serological response were age (<65a), history of anti-CD20 therapy within the year preceding vaccination, CD19[SUP]+[/SUP] B-cells < 110/µL, and CD4[SUP]+[/SUP] T-cells > 310/µL. The magnitude of T-cell response was higher in patients <65a and with CD19[SUP]+[/SUP] B-cells < 110/µL. Patients and healthy controls demonstrated a significant decrease in SARS-CoV-2 S antibody levels over the period of six months (p < 0.001). A third vaccination demonstrated a strong serological response in patients who had responded to the previous doses (p < 0.001). The third vaccination yielded seroconversion in three out of 19 patients in those without serological response. We conclude that both humoral and cellular responses after SARS-CoV-2 immunization are impaired in patients with hematological malignancies. A third vaccination enhanced B-cell response in patients who previously responded to the second vaccination but may be of limited benefit in patients without prior seroconversion.
Keywords: COVID-19; clinical trials; hematology–general; vaccine.